Oral antidiabetic drug use and associated health outcomes in cancer patients

X. Tan, X. Feng, J. Chang, G. Higa, Li Wang, Douglas Leslie

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

What is new and objective: To assess oral antidiabetic drug use and associated health outcomes in American non-elderly adults with cancer. Methods: A retrospective study was conducted by analysing the Marketscan® Commercial Claims and Encounters Database from 2008 to 2009. Individuals 18–64 years with concomitant diagnoses of cancer (breast, prostate, colon or lung) and type 2 diabetes, and treated with oral antidiabetic medications were included. Medication adherence was assessed using the Medication Possession Ratio (MPR); logistic regression was used to analyse factors associated with non-adherence. Adherence was compared between patients with cancer and non-cancer controls matched by propensity scores. Negative binomial regression was utilized to examine the effect of antidiabetic drug adherence on all-cause hospitalizations and emergency room visits. The impact of adherence on total medical costs was then evaluated using the generalized linear model (GLM) with the log-link function and gamma error distribution. Results and discussion: Of 1918 diabetic, cancer patients who newly initiated oral diabetic drugs, only 37·6% were adherent to oral diabetic medications; a similar proportion of adherence was found in the non-cancer control population (35·8%, P = 0·24). Younger age, living in the southern region, using combination therapy vs. monotherapy, and using retail pharmacy vs. mail order pharmacy were significantly associated with non-adherence in patients with cancer. Adherence to oral antidiabetic drugs was associated with 24% fewer all-cause hospitalizations (P = 0·02). What is new and conclusion: We identified high prevalence of non-adherence to oral antidiabetic medications as well as negative consequences associated with non-adherence, among patients with cancer. These findings may underscore the importance of developing relevant intervention strategies for improving diabetes management and treatment outcomes among cancer patients with diabetes.

Original languageEnglish (US)
Pages (from-to)524-531
Number of pages8
JournalJournal of Clinical Pharmacy and Therapeutics
Volume41
Issue number5
DOIs
StatePublished - Oct 1 2016

Fingerprint

Hypoglycemic Agents
Health
Neoplasms
Patient Compliance
Hospitalization
Propensity Score
Medication Adherence
Postal Service
Type 2 Diabetes Mellitus
Statistical Factor Analysis
Hospital Emergency Service
Linear Models
Prostatic Neoplasms
Colon
Retrospective Studies
Logistic Models
Databases
Breast Neoplasms
Costs and Cost Analysis
Lung

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{e124739175f74f23ac753cc7cde86cee,
title = "Oral antidiabetic drug use and associated health outcomes in cancer patients",
abstract = "What is new and objective: To assess oral antidiabetic drug use and associated health outcomes in American non-elderly adults with cancer. Methods: A retrospective study was conducted by analysing the Marketscan{\circledR} Commercial Claims and Encounters Database from 2008 to 2009. Individuals 18–64 years with concomitant diagnoses of cancer (breast, prostate, colon or lung) and type 2 diabetes, and treated with oral antidiabetic medications were included. Medication adherence was assessed using the Medication Possession Ratio (MPR); logistic regression was used to analyse factors associated with non-adherence. Adherence was compared between patients with cancer and non-cancer controls matched by propensity scores. Negative binomial regression was utilized to examine the effect of antidiabetic drug adherence on all-cause hospitalizations and emergency room visits. The impact of adherence on total medical costs was then evaluated using the generalized linear model (GLM) with the log-link function and gamma error distribution. Results and discussion: Of 1918 diabetic, cancer patients who newly initiated oral diabetic drugs, only 37·6{\%} were adherent to oral diabetic medications; a similar proportion of adherence was found in the non-cancer control population (35·8{\%}, P = 0·24). Younger age, living in the southern region, using combination therapy vs. monotherapy, and using retail pharmacy vs. mail order pharmacy were significantly associated with non-adherence in patients with cancer. Adherence to oral antidiabetic drugs was associated with 24{\%} fewer all-cause hospitalizations (P = 0·02). What is new and conclusion: We identified high prevalence of non-adherence to oral antidiabetic medications as well as negative consequences associated with non-adherence, among patients with cancer. These findings may underscore the importance of developing relevant intervention strategies for improving diabetes management and treatment outcomes among cancer patients with diabetes.",
author = "X. Tan and X. Feng and J. Chang and G. Higa and Li Wang and Douglas Leslie",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/jcpt.12430",
language = "English (US)",
volume = "41",
pages = "524--531",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "5",

}

Oral antidiabetic drug use and associated health outcomes in cancer patients. / Tan, X.; Feng, X.; Chang, J.; Higa, G.; Wang, Li; Leslie, Douglas.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 41, No. 5, 01.10.2016, p. 524-531.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oral antidiabetic drug use and associated health outcomes in cancer patients

AU - Tan, X.

AU - Feng, X.

AU - Chang, J.

AU - Higa, G.

AU - Wang, Li

AU - Leslie, Douglas

PY - 2016/10/1

Y1 - 2016/10/1

N2 - What is new and objective: To assess oral antidiabetic drug use and associated health outcomes in American non-elderly adults with cancer. Methods: A retrospective study was conducted by analysing the Marketscan® Commercial Claims and Encounters Database from 2008 to 2009. Individuals 18–64 years with concomitant diagnoses of cancer (breast, prostate, colon or lung) and type 2 diabetes, and treated with oral antidiabetic medications were included. Medication adherence was assessed using the Medication Possession Ratio (MPR); logistic regression was used to analyse factors associated with non-adherence. Adherence was compared between patients with cancer and non-cancer controls matched by propensity scores. Negative binomial regression was utilized to examine the effect of antidiabetic drug adherence on all-cause hospitalizations and emergency room visits. The impact of adherence on total medical costs was then evaluated using the generalized linear model (GLM) with the log-link function and gamma error distribution. Results and discussion: Of 1918 diabetic, cancer patients who newly initiated oral diabetic drugs, only 37·6% were adherent to oral diabetic medications; a similar proportion of adherence was found in the non-cancer control population (35·8%, P = 0·24). Younger age, living in the southern region, using combination therapy vs. monotherapy, and using retail pharmacy vs. mail order pharmacy were significantly associated with non-adherence in patients with cancer. Adherence to oral antidiabetic drugs was associated with 24% fewer all-cause hospitalizations (P = 0·02). What is new and conclusion: We identified high prevalence of non-adherence to oral antidiabetic medications as well as negative consequences associated with non-adherence, among patients with cancer. These findings may underscore the importance of developing relevant intervention strategies for improving diabetes management and treatment outcomes among cancer patients with diabetes.

AB - What is new and objective: To assess oral antidiabetic drug use and associated health outcomes in American non-elderly adults with cancer. Methods: A retrospective study was conducted by analysing the Marketscan® Commercial Claims and Encounters Database from 2008 to 2009. Individuals 18–64 years with concomitant diagnoses of cancer (breast, prostate, colon or lung) and type 2 diabetes, and treated with oral antidiabetic medications were included. Medication adherence was assessed using the Medication Possession Ratio (MPR); logistic regression was used to analyse factors associated with non-adherence. Adherence was compared between patients with cancer and non-cancer controls matched by propensity scores. Negative binomial regression was utilized to examine the effect of antidiabetic drug adherence on all-cause hospitalizations and emergency room visits. The impact of adherence on total medical costs was then evaluated using the generalized linear model (GLM) with the log-link function and gamma error distribution. Results and discussion: Of 1918 diabetic, cancer patients who newly initiated oral diabetic drugs, only 37·6% were adherent to oral diabetic medications; a similar proportion of adherence was found in the non-cancer control population (35·8%, P = 0·24). Younger age, living in the southern region, using combination therapy vs. monotherapy, and using retail pharmacy vs. mail order pharmacy were significantly associated with non-adherence in patients with cancer. Adherence to oral antidiabetic drugs was associated with 24% fewer all-cause hospitalizations (P = 0·02). What is new and conclusion: We identified high prevalence of non-adherence to oral antidiabetic medications as well as negative consequences associated with non-adherence, among patients with cancer. These findings may underscore the importance of developing relevant intervention strategies for improving diabetes management and treatment outcomes among cancer patients with diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84983371986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983371986&partnerID=8YFLogxK

U2 - 10.1111/jcpt.12430

DO - 10.1111/jcpt.12430

M3 - Article

C2 - 27453485

AN - SCOPUS:84983371986

VL - 41

SP - 524

EP - 531

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 5

ER -